drugset / Trial / NCT05525637

Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

NCT05525637

Phase 3 Completed 1037 enrolled Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess efficacy and safety of YZJ-1139 in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

Timeline

Start
2021-12-17
Primary completion
2023-07-07
Completion
2023-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject FAZAMOREXANT Small molecule 20 mg
Subject FAZAMOREXANT Small molecule 40 mg

Indications